WO2011018587A3 - OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE - Google Patents

OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE Download PDF

Info

Publication number
WO2011018587A3
WO2011018587A3 PCT/FR2010/051702 FR2010051702W WO2011018587A3 WO 2011018587 A3 WO2011018587 A3 WO 2011018587A3 FR 2010051702 W FR2010051702 W FR 2010051702W WO 2011018587 A3 WO2011018587 A3 WO 2011018587A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
activating
preparation
therapeutic use
fgf receptor
Prior art date
Application number
PCT/FR2010/051702
Other languages
English (en)
Other versions
WO2011018587A2 (fr
Inventor
Philippe Duchaussoy
Pierre Fons
Alexandre Froidbise
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2012109572/04A priority Critical patent/RU2559629C2/ru
Priority to SG2012010211A priority patent/SG178406A1/en
Priority to BR112012002980A priority patent/BR112012002980A2/pt
Priority to EP10761048A priority patent/EP2464359A2/fr
Priority to KR1020127006509A priority patent/KR20120059552A/ko
Priority to MX2012001945A priority patent/MX2012001945A/es
Priority to CN201080046342.7A priority patent/CN102625704B/zh
Priority to JP2012524264A priority patent/JP5732460B2/ja
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to CA2771055A priority patent/CA2771055C/fr
Priority to AU2010283613A priority patent/AU2010283613B2/en
Publication of WO2011018587A2 publication Critical patent/WO2011018587A2/fr
Publication of WO2011018587A3 publication Critical patent/WO2011018587A3/fr
Priority to US13/369,677 priority patent/US9527930B2/en
Priority to IL218069A priority patent/IL218069A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)

Abstract

Oligosaccharides N-sulfates activateurs des récepteurs des FGFs, répondant à la formule (I); dans laquelle; R1, R4, R6 et R8 représentent des groupes -OSO3 - ou hydroxyle, R2 représente un groupe -O-alkyle ou un monosaccharide de formule (II), R3 représente un disaccharide de formule (III), R5 représente un disaccharide de formule (IV), R7 représente un groupe hydroxyle ou un disaccharide de formule (Vl) : R9 représente un groupe hydroxyle ou -O-alkyle ou un disaccharide de formule (VII), où R10 représente un groupe -O-alkyle : Leur préparation et leur application en thérapeutique.
PCT/FR2010/051702 2009-08-14 2010-08-12 OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE WO2011018587A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201080046342.7A CN102625704B (zh) 2009-08-14 2010-08-12 活化成纤维细胞生长因子受体的n-硫酸盐低聚糖,其制备,及其治疗用途
BR112012002980A BR112012002980A2 (pt) 2009-08-14 2010-08-12 oligossacarídeo n-sulfatos ativadores dos receptores dos fgfs, o respectivo preparo e a repectiva utilização em terapêutica
EP10761048A EP2464359A2 (fr) 2009-08-14 2010-08-12 OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
KR1020127006509A KR20120059552A (ko) 2009-08-14 2010-08-12 Ｆｇｆ 수용체-활성화 ｎ-술페이트 올리고사카라이드, 그의 제조법, 및 그의 치료 용도
MX2012001945A MX2012001945A (es) 2009-08-14 2010-08-12 Oligosacaridos n-sulfatados activadores de los receptores de fgf, su preparacion y su uso en terapeutica.
RU2012109572/04A RU2559629C2 (ru) 2009-08-14 2010-08-12 N-сульфатированные олигосахариды, активирующие рецепторы fgf, их получение и применение в терапии
JP2012524264A JP5732460B2 (ja) 2009-08-14 2010-08-12 Ｆｇｆ受容体活性化ｎ−硫酸塩オリゴ糖、該オリゴ糖の調製および該オリゴ糖の治療用途
SG2012010211A SG178406A1 (en) 2009-08-14 2010-08-12 Fgf receptor-activating n-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof
CA2771055A CA2771055C (fr) 2009-08-14 2010-08-12 Oligosaccharides n-sulfates activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
AU2010283613A AU2010283613B2 (en) 2009-08-14 2010-08-12 FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof
US13/369,677 US9527930B2 (en) 2009-08-14 2012-02-09 FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof
IL218069A IL218069A (en) 2009-08-14 2012-02-12 Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0903969 2009-08-14
FR0903969A FR2949115B1 (fr) 2009-08-14 2009-08-14 OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/369,677 Continuation US9527930B2 (en) 2009-08-14 2012-02-09 FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2011018587A2 WO2011018587A2 (fr) 2011-02-17
WO2011018587A3 true WO2011018587A3 (fr) 2011-07-07

Family

ID=41826877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/051702 WO2011018587A2 (fr) 2009-08-14 2010-08-12 OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE

Country Status (16)

Country Link
US (1) US9527930B2 (fr)
EP (1) EP2464359A2 (fr)
JP (1) JP5732460B2 (fr)
KR (1) KR20120059552A (fr)
CN (2) CN102625704B (fr)
AR (1) AR078093A1 (fr)
AU (1) AU2010283613B2 (fr)
BR (1) BR112012002980A2 (fr)
CA (1) CA2771055C (fr)
FR (1) FR2949115B1 (fr)
IL (1) IL218069A (fr)
MX (1) MX2012001945A (fr)
MY (1) MY160505A (fr)
RU (1) RU2559629C2 (fr)
SG (1) SG178406A1 (fr)
WO (1) WO2011018587A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949115B1 (fr) 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2970969B1 (fr) * 2011-01-27 2013-10-18 Sanofi Aventis Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018546A1 (fr) * 1991-04-17 1992-10-29 Glycomed, Inc. Polysaccharides sulfates en tant qu'inhibiteurs de la proliferation cellulaire dans les muscles lisses
FR2800074A1 (fr) * 1999-10-22 2001-04-27 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US20040068108A1 (en) * 1996-06-14 2004-04-08 Philippe Duchaussoy Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
EP0300099A1 (fr) 1987-07-20 1989-01-25 Akzo N.V. Pentasaccharides
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
FR2704226B1 (fr) 1993-04-22 1995-07-21 Sanofi Elf 3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NZ264340A (en) 1993-09-01 1995-04-27 Akzo Nobel Nv Bisconjugate comprising two saccharides and a spacer, use in pharmaceutical compositions
FR2751334B1 (fr) 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6617316B1 (en) 1999-10-22 2003-09-09 Aventis Pharma Oligosaccharides, their preparation and pharmaceutical compositions containing them
PT2343077E (pt) * 2001-09-12 2013-08-29 Sigma Tau Res Switzerland Sa Derivados de glicosaminoglicanos totalmente n-dessulfatados como inibidores da heparanase, capazes de atividade antiangiogénica e desprovidos de efeito anticoagulante
RU2333222C2 (ru) * 2002-06-18 2008-09-10 Гликорес 2000 С.Р.Л. Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования
US7582737B2 (en) * 2004-07-20 2009-09-01 Academia Sinica Orthogonally protected disaccharide building blocks for synthesis of heparin oligosaccharides
FR2873377B1 (fr) 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949115B1 (fr) 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018546A1 (fr) * 1991-04-17 1992-10-29 Glycomed, Inc. Polysaccharides sulfates en tant qu'inhibiteurs de la proliferation cellulaire dans les muscles lisses
US20040068108A1 (en) * 1996-06-14 2004-04-08 Philippe Duchaussoy Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
FR2800074A1 (fr) * 1999-10-22 2001-04-27 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. TABEUR ET AL.: "Oligosaccharides corresponding to the regular sequence of heparin: chemical synthesis and interaction with FGF-2", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 7, 1999, pages 2003 - 2012, XP002575365 *
CODEE J D C ET AL: "The synthesis of well-defined heparin and heparan sulfate fragments", DRUG DISCOVERY TODAY: TECHNOLOGIES, ELSEVIER, vol. 1, no. 3, 1 December 2004 (2004-12-01), pages 317 - 326, XP004767969, ISSN: 1740-6749 *

Also Published As

Publication number Publication date
AU2010283613B2 (en) 2016-03-10
RU2559629C2 (ru) 2015-08-10
RU2012109572A (ru) 2013-09-20
CN102625704A (zh) 2012-08-01
IL218069A (en) 2015-04-30
CA2771055C (fr) 2017-05-09
JP5732460B2 (ja) 2015-06-10
US20120202769A1 (en) 2012-08-09
KR20120059552A (ko) 2012-06-08
IL218069A0 (en) 2012-04-30
MY160505A (en) 2017-03-15
FR2949115A1 (fr) 2011-02-18
MX2012001945A (es) 2012-06-27
BR112012002980A2 (pt) 2016-04-19
FR2949115B1 (fr) 2012-11-02
EP2464359A2 (fr) 2012-06-20
US9527930B2 (en) 2016-12-27
CN104945524A (zh) 2015-09-30
AU2010283613A1 (en) 2012-03-08
AR078093A1 (es) 2011-10-12
CN102625704B (zh) 2015-05-06
JP2013501838A (ja) 2013-01-17
SG178406A1 (en) 2012-03-29
CA2771055A1 (fr) 2011-02-17
WO2011018587A2 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
WO2011044501A3 (fr) Analogues d'aminoglycoside antibactériens
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2014004902A3 (fr) Amélioration de l'autophagie ou augmentation de la longévité par l'administration d'urolithines ou de précurseurs de celles-ci
WO2010141796A3 (fr) Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
WO2008126752A1 (fr) Agent d'éclaircissement de la peau contenant un composé d'équol en tant que principe actif
WO2010132765A3 (fr) Analogues d'aminoglycoside antibactériens
MX349153B (es) Diversificacion de oligosacaridos de leche humana (hmo) o precursores de los mismos.
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2008135791A8 (fr) Imidazoquinolines dotées de propriétés immuno-modulatrices
WO2014018596A3 (fr) Alpha (1,2) fucosyltransférases appropriées pour une utilisation dans la production d'oligosaccharides fucosylés
WO2011066352A8 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
WO2008086269A3 (fr) Composés 6-aminoisoquinoline
MX2012014423A (es) Forma cristalina de bencilbenceno inhibidor de sglt2.
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
WO2012117357A3 (fr) Procédé de préparation d'intermédiaires de cétolides
WO2011018587A3 (fr) OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
WO2011018588A3 (fr) OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
WO2012038979A3 (fr) Procédé de préparation d'ertapénem
WO2007098189A3 (fr) Nouvelle forme cristalline et compositions pharmaceutiques de (+)-r-zileuton
PL1846430T3 (pl) Nowe makrolidy
WO2011038234A3 (fr) Nouveaux dérivés d'iodo pyrimidines utiles pour le traitement de maladies ou affections liées au facteur inhibiteur de la migration des macrophages
WO2010054606A3 (fr) 2-désoxy glycosides triterpénoïdes, leur procédé de préparation et leur utilisation en tant que médicaments
WO2009137130A3 (fr) Analogues de fluoroquinolones antibactériens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080046342.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761048

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010761048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 288/KOLNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 218069

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010283613

Country of ref document: AU

Ref document number: 2771055

Country of ref document: CA

Ref document number: 2012524264

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/001945

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010283613

Country of ref document: AU

Date of ref document: 20100812

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127006509

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012109572

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012002980

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012002980

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120209